Clinical trial
Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic…
NCT00305734 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00305734 |
|---|---|
| Title | Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer |
| Official title | Phase II Trial of PS-341 (Bortezomib, NSC-681239) Followed by the Addition of Gemcitabine at Progression in Recurrent or Metastatic Nasopharyngeal Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer |
| Intervention type | Drug, Other |
| Interventions | bortezomib, gemcitabine hydrochloride, laboratory biomarker analysis |
| Enrollment | 50 |
| Start date | Aug 1, 2006 |
| Primary completion | Jul 1, 2007 |
| First posted | Mar 22, 2006 |
| Last update posted | Jan 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: